Therapy of anogenital HPV-induced lesions

Clinics in Dermatology

Volumn 15, Issue 3, 1997, Pages 457-470

  Gross, Gerd ^a   Von Krogh, Geo ^b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ALPHAN3 INTERFERON; BETA INTERFERON; CHO BETA GEL; CIDOFOVIR; CYTOTOXIC AGENT; EMLA; FLUOROPELEX; FLUOROURACIL; IMIQUIMOD; INTERLEUKIN 2; LIDOCAINE; PODOPHYLLIN; PODOPHYLLOTOXIN; PODOX; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RETINOID; TRICHLOROACETIC ACID; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CARBON DIOXIDE LASER; CHILL; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOTHERAPY; DIATHERMY; DRUG FORMULATION; DRUG MIXTURE; FEVER; HEADACHE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; INTRAVAGINAL DRUG ADMINISTRATION; LEUKOPENIA; MYALGIA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; SKIN DEFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; TOPICAL DRUG ADMINISTRATION; UTERINE CERVIX CARCINOMA; VERRUCA VULGARIS; WART VIRUS;

EID: 0030740472     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00152-6     Document Type: Article

References (127)

1. Filiberti A, Tamburini A, Stefanon B, et al. Psychological aspects of genital human papillomavirus infection: a preliminary report. J Psychosom Gynaecol 1993;14:145-52.
2. American Social Health Association. Survey shows how we live with HPV. HPV News 1993;3:1-9.
3. Goodkin K, Antoni MH, Helder L, et al. Psychoneuroimmunological aspects of disease progression among women with human papillomavirus-associated cervical dysplasia and human immunodeficiency virus type 1 coinfection. Int J Psych Med 1993;23:119-48.
4. Krebs H-B, Helmkamp BF. Does the treatment of genital condylomata in men decrease the treatment failure rate of cervical dysplasia in the female sexual partner? Obstet Gynecol 1990;76:660-3.
5. Ward BG, Thomas IL. Randomized prospective intervention study of human cervical wart virus infection. Aust NZ J Obstet Gynecol 1994;34:182-5.
6. American Academy of Dermatology Task Force on Pediatric Dermatology. Genital warts and sexual abuse in children. J Am Acad Dermatol 1984;11:529-30.
7. Lacey CJN. Genital warts in children. Papilloma Virus Report 1991;2:31-3.
8. Handley J, Dinsmore E, Maw R, et al. Anogenital warts in prepubertal children; Sexual abuse or not? Int J STD & AIDS 1993;4:271-9.
9. Gross G. Treatment of human papillomavirus infection. In: Mindel A, editor. Genital warts. Human papillomavirus infection. London, Boston, Melbourne, Auckland: Edward Arnold, 1995;198-236.
10. Von Krogh G, Wikström A. Efficacy of chemical and / or surgical therapy against condylomata acuminata: a retrospective evaluation. Int J STD & AIDS 1993;2:333-8.
11. Genital human papillomavirus infections and cancer: memorandum from a WHO meeting. Bull WHO 1987; 65:817-27.
12. Kaplan JW. Condylomata acuminata. N Orleans Med 1942;94:388-90.
13. Von Krogh G. Podophyllotoxin for condylomata acuminata eradication. Clinical and experimental comparative studies on podophyllum lignans, colchicine and 5-fluoruracil (Thesis) Acta Dermato Venereol (Stockh) (Suppl. 98) 1981.
14. Bashi SA. Cryotherapy versus podophyllin in the treatment of genital warts. Int J Dermatol 1985;24:535-6.
15. Jensen SL. Comparison of podophyllin application with simple excision in clearance and recurrence of perianal condylomata acuminata. Lancet 1985;2:1146-8.
16. Lassus A. Comparison of podophyllotoxin and podophyllin in treatment of genital warts. Lancet 1987;2: 512-3.
17. Mazurkiewicz W, Jablonska S. Comparison between the therapeutic efficacy of 0.5% podophyllotoxin preparation and 20% podophyllin ethanol solution in condylomata acuminata. Z Hautkr 1986;61:1387-95.
18. Edwards A, Atma-Ram A, Thin RN. Podohyllotoxin 0.5% versus podophyllin 20% to treat penile warts. Genitourin Med 1988;64:263-5.
19. Mazurkiewicz W, Jablonska S. Clinical efficacy of condyline (0.5% podophyllotoxin) solution and cream versus podophyllin in the treatment of external condylomata acuminata. J Dermatol Treatment 1990;1:123-5.
20. Von Krogh G. Topical treatment of HPV lesions of the external genitalia. The Cervix 1992;10,125-31.
21. Cassidy DE, Drewry J, Fanning JP. Podophyllum toxicity: A review of a fatal case and a review of the literature. J Toxicol-Clin Toxicol 1982;19(1),35-44.
22. Filley CM, Graff-Radford NR, Lacy R, et al. Neurological manifestations of podophyllin toxicity. Neurology 1982; 32:308-11.
23. Von Krogh G. Podophyllotoxin in serum: absorption subsequent to three-day repeated application of a 0.5% ethanolic preparation on condylomata acuminata. Sex Transm Dis, 1982;9,26-33.
24. West WM, Ridgeway NA, Morris AJ, et al. Fatal podophyllin ingestion. Southern Med J 1982;75(10):1269-70.
25. Sand PC, Weissmann K. Quercetin and kaempherol: an argument against the use of podophyllin? Genitourin Med 1995;71:92-3.
26. Cairney M, Campo MS. The synergism between bovine papillomavirus type 4 and quercitin is dependent on the timing of exposure. Carcinogenesis 1995;16:1997-2001.
27. Mansono-Martinez R. Podophyllotoxin poisoning of microtubules of steady-state. Effect of substoichiometric and superstoichiometric concentrations of the drug. Mol Cell Biochem 1982;45:3-11.
28. Von Krogh G. Penile condylomata acuminata: an experimental model for evaluation of topical treatment with 0.5-1.0% ethanolic preparations of podophyllotoxin for three days. Sex Transm Dis 1981;8:179-86.
29. Kraus SJ, Stone KM. Management of genital infection caused by human papillomaviruses. Rev Infect Dis 1990;12(Suppl. 6),S620-63.
30. Mohanty KC. The cost effectiveness of treatment of genital warts with podophyllotoxin. Int J STD & AIDS 1994; 5:253-6.
31. Loike JD, Horowitz SB. Effects of podophyllotoxin and VP-16-213 on microtubule assembly in vitro and nucleoside transport in HeLa cells. Biochemistry 1976;15:5435-42.
32. Von Krogh G, Maibach HI. Cutaneous cytodestructive potency of lignans. I. A comparative evaluation of influence on epidermal and dermal DNA synthesis and on dermal microcirculation in the hairless mouse. Arch Dermatol Res 1982;274:9-20.
33. Von Krogh G, Maibach HI. Cutaneous cytodestructive potency of lignans. II. A comparative evaluation of macroscopic-toxic influence on rabbit skin subsequent to repeated 10-day applications. Dermatologica 1983;167: 70-7.
34. Sullivan M, King L. Effects of resin of podophyllin on normal skin, condylomata acuminata and verrucae vulgares. Arch Dermatol Syph (Berlin) 1947;56:30-2.
35. Pickering RW. The treatment of condylomata acuminata - results of a questionnaire survey. Br J Sex Med 1989;210-3.
36. Beutner KR, Conant MA, Friedman-Kien A. Patient-applied podofilox for treatment of genital warts. Lancet 1989;1:831-4.
37. Kirby P, Dunne A, King DH, et al. Double-blind randomized clinical trial of self-administered podofilox solution vehicle in the treatment of genital warts. Am J Med 1990; 88:465-9.
38. Beutner KR, von Krogh G. Current status of podophyllotoxin for the treatment of genital warts. Semin Dermatol 1990;9:148-51.
39. Ljunghall K, Podophyllotoxin for treatment of genital warts in females. In: von Krogh G, Rylander E, editors. Genital papilloma virus infection. A survey for the clinician. Karlstad, Sweden: Conpharm AB, 1989;127-77.
40. Von Krogh G, Szpak E, Andersson M, et al. Self-treatment using 0.25-0.5% podophyllotoxin ethanol solutions against penile condylomata acuminata: a placebo-controlled comparative study. Genitourin Med 1994;70:105-9.
41. Von Krogh G, Hellberg D. Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women. A placebo controlled double-blind study. Sex Transm Dis 1992;19:170-4.
42. Hellberg D, Svarrer T, Nilsson S, et al. Self-treatment of female external warts with 0.5% podophyllotoxin cream (Condyline®) versus weekly application of 20% podophyllin solution. Int J STD & AIDS 1995;6:257-61.
43. Von Krogh G, Rosén B, Wartec Cream clinical expert report (Conpharm AB), (unpublished manuscript).
44. Strand A, Brinkeborn R-M, Siboulet A, Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution. Genitourin Med (in press).
45. Malvija VK, Deppe G, Pluszczynski R, et al. Trichloroacetic acid in the treatment of human papillomavirus infection of the cervix without associated dysplasia. Obstet Gynecol 1987;70:72-4.
46. Von Krogh G. 5-Fluorouracil cream in the successful treatment of therapeutically refractory condylomata acuminata of the urinary meatus. Acta Dermatol Venereol (Stockh) 1976;56:297-300.
47. 2 laser for treatment of vaginal condylomata. Obstet Gynecol 1984;64:773-8.
48. Krebs HB. Treatment of extensive condylomata acuminata with topical 5-fluorouracil. South Med J 1990;83: 761-4.
49. Pride GL. Treatment of large lower genital tract condylomata acuminata with topical 5-fluorouracil. J Reprod Med 1990;35:384-7.
50. Krebs HB. Prophylactic topical 5-fluorouracil following treatment of human papillomavirus-associated lesions of the vulva and vagina. Obstet Gynecol 1986;68:837-41.
51. Reid R, Greenberg MD, Lorincz AT, et al. Superficial laser vaporization and adjunctive 5-fluorouracil therapy of human papillomavirus-associated vulvar disease. Obstet Gynecol 1990;76:439-48.
52. Cetti NE. Condyloma acuminatum of the urethra: problems in eradication. Br J Surg 1984;71:57.
53. Wein AJ, Benson GS. Treatment of urethral condylomata acuminata with 5-FU cream. J Urol 1977;9:413-5.
54. Handley J, Dinsmore W. Treatment of anogenital warts. J Eur Acad Dermatol Venerol 1994;3:251-65.
55. Thomson JP. Perianal and anal condylomata acuminata. In: Todd IP, editor. Operative surgery colon rectum and anus. London: Butterworth, 1977:376-7.
56. Thomson JPS, Grace RH. The treatment of perianal and anal condyloma acuminata: a new operative technique. J Roy Soc Med 1978;71:180-5.
57. Rylander E, Sjöberg, I, Lilleborg S. Local anaesthesia of the genital mucosa with a lidocaine / prilocaine cream (EMLA™) for laser treatment of condylomata acuminata. A placebo-controlled study. Obstet Gynecol 1990;75: 302-6.
58. Samenius B. Perianal and ano-rectal condyloma acuminata. Schweiz Rundschau Med 1983;72:1009-14.
59. McMillan A, Scott GR. Outpatient treatment of perianal warts by scissor excision. Genitourin Med. 1987;63:114-5.
60. Scoular A. Choosing equipment for treating genital warts in genitourinary medicine clinics. Genitourin Med 1991;413-9.
61. Luchtfedl MA. Perianal condylomata acuminata. Surg Clin North Amer 1994;74:1327-38.
62. McKenna JG, Mcmillan A. Management of intrameatal warts in men. Int J STD & AIDS 1990;1:259-63.
63. Wright TC, Ganon S, Richart R, et al. Treatment of CIN using the loop surgical excison procedure. Obstet Gynecol 1992;79:173-8.
64. Prendiville W, Cullimore J, Norman S. Large loop excision of the transformation zone (LETZ). A method of management for women with cervical intraepithelial neoplasia. Br J Obstet Gynecol 1989;96:1055-60.
65. Luesley DM, Cullimore J, Redman CWE. Loop diathermy excision of the cervical transformation zone in patients with abnormal cervical smears. Br Med J 1990;300: 1690-93.
66. 2 laser conization and the loop electrosurgical excision procedure. Obstet Gynecol 1992;79: 147-53.
67. Torre D. In: Zacarian SA, editor. Instrumentation and Monitoring Devices in Cryosurgery. Cryosurgery for Skin Cancer and Cutaneous Disorders. St. Louis: CV Mosby, 1985:31-40.
68. Bergman A, Matsunaga J, Bhatia NN. Cervical cryotherapy for condylomata acuminata during pregnancy. Obstet Gynecol 1987;69:47-50.
69. Matsunaga J, Bergman A, Bhatia NN. Genital condylomata acuminata in pregnancy: effectiveness, safety and pregnancy outcome following cryotherapy. Br J Obstet Gynecol 1987;94:168-72.
70. Ferenczy A. Comparison of cryo-and carbon dioxide laser therapy for cervical intraepithelial neoplasia. Obstet Gynecol 1985;66:793-7.
71. Ferenczy A. Epidemiology and clinical pathology of condylomata acuminata. Am J Obstet Gynecol 1995;172: 1331-9.
72. Baggish MS. Improved laser techniques for the elimination of genital and extragenital warts. Am J Obstet Gynecol 1985;153:545-50.
73. Levavi H, Ovadia J. Swift lase scanner - A new modality in laser treatment of the vulva: effect on post-operative pain. Presented at the 8th World Congress of Cervical Pathology and Colposcopy - May 1993, Chicago IL, U.S.A.
74. Anderson MC, Hartley RB. Cervical crypt involvement by intraepithelial neoplasia. Obstet Gynecol 1980;55:546-50.
75. Larsson G, Alm P, Grundsell H, Laser conization versus cold knife conization. Surg Gynecol Obstet 1982;154:59-62.
76. Townsend DE, Levine RU, Crum DP, et al. Treatment of vaginal carcinoma in situ with the carbon dioxide laser. Am J Obstet Gynecol 1982;143:546-7.
77. Baggish MS, Dorsey JH. Carbon dioxide laser for combination excisional-vaporization conization. Am J Obstet Gynecol 1985;151:23-7.
78. Stanhope CR, Phibbs GD, Stuart GC, et al. Carbon dioxide laser surgery. Obstet Gynecol 1983;61(5):624-47.
79. Landthaler M, Haina D, Brunner R, et al. Laser therapy of bowenoid papulosis and Bowen's disease. J Derm Surg Oncol 1986;12:1253-7.
80. Ferenczy A. Laser therapy of genital condylomata acuminata. Obstet Gynecol 1984;63:703-7.
81. Garden JM, O'Banion MK, Shelnitz LS, et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. JAMA 1988;259:1199-202.
82. Abrahamson AL, Dilorenzo TP, Steinberg BM. Is papillomavirus detectable in the plume of laser-treated laryngeal papilloma? Arch Otolaryngol Head Neck Surg 1990; 116:604-7.
83. 2-laser-generated plume of smoke and its consequences to surgeon. Obstet Gynecol 1990;75:114-8.
84. Diaz MO, Bohlander S, Allen G. Nomenclature of human interferon genes. J. Interferon Res 1993;13:234-43.
85. Kalvakolanu DV, Borden EC. An overview of the interferon system: signal transduction and mechanism of action. Cancer Invest 1996;14(1):25-53.
86. Gross G, Ikenberg H, Roussaki A. Systemic treatment of condylomata acuminata with recombinant interferon alpha-2a: low dose superior to high-dose regimen. Chemotherapy 1986;32:537-41.
87. Gross G. Interferons in genital HPV disease. In: Gross G, Jablonska S, Pfister H, et al, editors. Genital papillomavirus infections. Berlin, Heidelberg, New York: Springer Verlag 1990:393-412.
88. Rockley PF, Tyring SK. Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections. Pharma Ther 1995;65:265-87.
89. Gross G. Interferons. In: Elsner P, Eichmann A, editors. Sexually transmitted diseases. Advances in diagnosis and treatment. Curr Probl Dermatol 1996;24:233-46.
90. Gross G, Roussaki A, Pfister H. Recurrent vulvar Buschke-Löwenstein tumor-like condylomata acuminata and Hodgkin's disease effectively treated with recombinant interferon alpha-2c gel as adjuvant to electrosurgery. Curr Probl Dermatol 1989;18:178-84.
91. Bornstein J, Pascal B, Abramovici H. Treatment of a patient with vulvar vestibulitis by intramuscular interferon beta; a case report. Eur J Obstet Gynecol Reprod Biol. 1991;42:237-9.
92. Ikic D, Bosnic N, Smerdel S. Double-blind clinical study with human leukocyte interferon in the therapy of condylomata acuminata. Proc Symp Clin Use Interferon, Zagreb 1975;167-77.
93. Möller BR, Johannesen P, Osther K, et al. Treatment of dysplasia of the cervical epithelium with an interferon gel. J Obstet Gynecol 1983;62:625-9.
94. Marcovici R, Peretz BA, Paldi E. Human fibroblast interferon therapy in patients with condylomata acuminata. Isr J Med Sci 1983;19:104.
95. Vesterinen E, Meyer B, Cantell K, et al. Topical treatment of flat vaginal condyloma with human leukocyte interferon. Obstet Gynecol 1984;64:535-8.
96. De Virgilis C, Crippa L, Leopardi O, et al. The role of beta-interferon in the therapy of female genital viral diseases. Int J Immunol 1987;3:147-50.
97. Schneider A, Papendick U, Gissmann L. Interferon treatment of human genital papillomavirus infections: Importance of viral type. Int J Cancer 1987;3:147-50.
98. Keay S, Teng N, Eisenberg M, et al. Topical interferon for treating condylomata acuminata in women. J Infect Dis 1988;185:934-9.
99. Syed TA, Cheema KM, Ahmad SA, et al. Human leukocyte interferon-alpha versus podophyllotoxin in cream for the treatment of genital warts in males. Dermatology 1995;191:129-32.
100. Eron LJ, Judson F, Tucker S, et al. Interferon therapy for condylomata acuminata. N Engl J Med 1986;315:1059-69.
101. Vance JC, Bart BJ, Hansen PC, et al. Intralesional recombinant alpha-2-interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol 1986;122:272-7.
102. Friedman-Kien A, Eron LJ, Conant M, et al. Natural interferon alpha for treatment of condylomata acuminata. JAMA 1988;259:533-8.
103. Reichman RC, Oakes D, Bonnez W, et al. Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind placebo-controlled trial. Ann Intern Med 1988;108:675-9.
104. Welander LE, Homesley HD, Smiles KA, et al. Intralesional interferon alpha-2b for the treatment of genital warts. Am J Obstet Gynecol 1990;162:348-54.
105. Douglas JM, Rogers U, Judson FN. The effect of asymptomatic infection with HTLV-3 on the response of anogenital warts to intralesional treatment with recombinant alpha-2-interferon. J Infect Dis 1986;154:331-4.
106. Friedman-Kien A. Management of condylomata acuminata with Alferon N Infection (interferon alpha-N3 human leukocyte derived). Am J Obstet Gynecol 1995;172:1359-68.
107. Gross G, Degen KW, Fierlbeck G, et al. Recombinant interferon gamma in anogenital warts: results of a multicentre placebo-controlled clinical trial. J Interferon Res 1991;11(Suppl 1):76.
108. Gross G, Roussaki A, Ikenberg H, et al. Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption. Dermatologica 1991;183:203-7.
109. Gross G, Rogozinski T, Schöfer H, et al. Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: Results of a placebo-controlled double-blind study in 120 patients. J Interferon Res 1994;14(Suppl 1):151.
110. 2-laser ablation. The influence of the cyclic low-dose therapy regimen. Results of a multicentre double-blind placebo-controlled clinical trial. Genitourin Med 1996;71.
111. Vance JC, Davis, D. Interferon alpha-2b injections used as an adjuvant therapy to carbon dioxide laser vaporization of recalcitrant anogenital condylomata acuminata. J Invest Dermatol 1990;995:146-8.
112. Davis BE, Noble MJ. Initial experience with combined interferon alpha and carbon dioxide laser for the treatment of condylomata acuminata. J Urol 1992;197:627-9.
113. Douglas JM Jr, Eron LJ, Judson FN, et al. A randomized trial of combination therapy with intralesional interferon alpha-2b and podophyllin versus podophyllin alone for the therapy of anogenital warts. J Infect Dis 1990;162:52-9.
114. Handley JM, Horner T, Maw RD, et al. Subcutaneous interferon alpha-2a combined with cryotherapy vs. cryotherapy alone in the treatment of primary anogenital warts: A randomised observer-blind placebo-controlled study. Genitourinary Med 1991;67:297-307.
115. Eron LJ, Alder MB, O'Rourke JM, et al. Recurrence of condylomata acuminata following cryotherapy is not prevented by systematically administered interferon. Genitourin Med 1993;69:91-3.
116. Hohenleutner U, Landthaler M, Braun-Falco O. Postoperative adjuvante therapie mit interferon-alpha-2b nach laserchirurgie von condylomata acuminata. Hautarzt 1990;41:545-8.
117. Petersen CS, Bjerring P, Larsen J, et al. Systemic interferon alpha-2b increases the cure rate in laser-treatment patients with multiple persistent genital warts: A placebo-controlled study. Genitourin Med 1991;67:99-102.
118. The Condylomata International Collaborative Study Group. Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic interferon-alpha-2a in the treatment of anogenital condylomata acuminata. J Infect Dis 1993;167:824-9.
119. Nieminen P, Aho M, Lehtinen M, et al. Treatment of genital HPV infection with carbon dioxide laser and systemic interferon alpha-2a. Sex Transm Dis 1994;21:59-65.
120. Armstrong DKB, Maw RD, Dinsmore WW, et al. Randomised, double-blind, parallel group study to compare subcutaneous interferon alpha-2a plus podophyllin with placebo plus podophyllin in the treatment of primary condylomata acuminata. Genitourin Med 1994;70:389-93.
121. Armstrong DKB, Maw RD, Dinsmore WW, et al. Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital warts. Genitourin Med 1996;72:103-7.
122. Reid R, Greenberg MD, Pezzuti DJ, et al. Superficial laser vulvectomy. V. Surgical debulking is enhanced by adjuvant systemic interferon. Am J Obstet Gynecol 1992;166:815-20.
123. Prümmer O, Gross G, Baur S, et al. The beneficial effect of low-dose interferon alpha-2a treatment in patients with condylomata acuminata is not impaired by interferon-alpha antibodies. J Interferon Cytokine Res (in press.)
124. Lippmann SM, Kavanagh JJ, Paredes-Espinoza M. 13-cisretinoic acid plus interferon-alpha-2a: Highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992;84:241-5.
125. Beutner K, Spruance S, Douglas J, et al. Double-blind, vehicle-controlled, randomized multicenter trial of 5% imiquimod cream for the treatment of genital and perianal warts, (abstract) 2nd Int Congress Papillomaviruses Hum Pathol, Paris, 1994.
126. Van Cutsem E, Snoeck R, van Ranst M, et al. Successful treatment of squamous papilloma of the hypopharynx-esophagus by local injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine. J Med Virol 1995;45:230-5.
127. De Clercq E, Holy A, Rosenberg I, et al. A novel selective broad-spectrum anti-DNA virus agent. Nature 1986;323: 464-7.